Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Connie Duong"'
Autor:
Alex Q. Lee, Hiroaki Konishi, Connie Duong, Sakiko Yoshida, Ryan R. Davis, Jonathan E. Van Dyke, Masami Ijiri, Bridget McLaughlin, Kyoungmi Kim, Yueju Li, Laurel Beckett, Nitin Nitin, John D. McPherson, Clifford G. Tepper, Noriko Satake
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
In leukemia, a distinct subpopulation of cancer-initiating cells called leukemia stem cells (LSCs) is believed to drive population expansion and tumor growth. Failing to eliminate LSCs may result in disease relapse regardless of the amount of non-LSC
Externí odkaz:
https://doaj.org/article/65345325b8c3492586a08bddfb989d5c
Autor:
Noriko Satake, Connie Duong, Sakiko Yoshida, Michael Oestergaard, Cathy Chen, Rachael Peralta, Shuling Guo, Punit P Seth, Yueju Li, Laurel Beckett, Jong Chung, Jan Nolta, Nitin Nitin, Joseph M Tuscano
Publikováno v:
Molecular Medicine, Vol 22, Iss 1, Pp 632-642 (2016)
Abstract The exponential rise in molecular and genomic data has generated a vast array of therapeutic targets. Oligonucleotide-based technologies to down regulate these molecular targets have promising therapeutic efficacy. However, there is relative
Externí odkaz:
https://doaj.org/article/88710ac9246b4db68143aad6fabf9036
Autor:
Alex Q, Lee, Hiroaki, Konishi, Connie, Duong, Sakiko, Yoshida, Ryan R, Davis, Jonathan E, Van Dyke, Masami, Ijiri, Bridget, McLaughlin, Kyoungmi, Kim, Yueju, Li, Laurel, Beckett, Nitin, Nitin, John D, McPherson, Clifford G, Tepper, Noriko, Satake
In leukemia, a distinct subpopulation of cancer-initiating cells called leukemia stem cells (LSCs) is believed to drive population expansion and tumor growth. Failing to eliminate LSCs may result in disease relapse regardless of the amount of non-LSC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9738f2e3ef2a4f37b49d8b2a8392f4e5
https://escholarship.org/uc/item/4kj8t74h
https://escholarship.org/uc/item/4kj8t74h
Autor:
Jennifer Wargo, Miles Andrews, Connie Duong, Vancheswaran Gopalakrishnan, Valerio Iebba, Wei-Shen Chen, Lisa Derosa, Bertrand Routy, Gladys Ferrere, Aurélie Fluckiger, Maria Roberti, Paule Opolon, Whijae Roh, Christine Spencer, Irina Fernandez Curbelo, Luis Vence, Alexandre Reuben, Zachary Cooper, Peter Prieto, M. A. Wadud Khan, Alexander Lazar, Michael Tetzlaff, Courtney Hudgens, Pierre-Olivier Gaudreau, Luigi Nezi, Didier Raoult, Lauren Haydu, Hussein Tawbi, Patrick Hwu, Wen-Jen Hwu, Rodabe Amaria, Elizabeth Burton, Scott Woodman, Adi Diab, Sapna Patel, Isabella Glitza, Jianhua Zhang, Nadim Ajami, Joseph Petrosino, Robert Jenq, Michael Davies, Jeffrey Gershenwald, Padmanee Sharma, James Allison, Andrew Futreal, Laurence Zitvogel, Maryam TIDJANI ALOU, Satoru Yonekura, Alexandria Cogdill, Reetakshi Arora, Latasha Little, Curtis Gumbs, Khalida Wani, Margaret Callahan, Mathew Adamow, Michael Postow, Charlotte Ariyan, Julie Gardner, Jennifer McQuade, Michael Wong, Li Zhao
Treatment with combined immune checkpoint blockade (CICB) targeting CTLA-4 and PD-1 is associated with clinical benefit across tumor types, but a high rate of immune-related adverse events (irAE). Insights into biomarkers and mechanisms of response a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24dcf02e4ee91c54a0239c73fe7cba34
https://doi.org/10.21203/rs.3.rs-119925/v1
https://doi.org/10.21203/rs.3.rs-119925/v1